Rights and permissions
About this article
Cite this article
Cost-benefit argument favours medroxyprogesterone. Pharmacoecon. Outcomes News 24, 11 (1995). https://doi.org/10.1007/BF03309545
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03309545